Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients

May 05th, 2008 | Category: Cancer

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that it has initiated a Phase 2a clinical trial of Azedra (Ultratrace™ iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma, a neuroendocrine

cancer that primarily affects children. Azedra is already being evaluated in an ongoing dose-ranging clinical trial for pheochromocytoma in adults.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results Of Azedra™ Phase I Trial In Neuroendocrine Cancer Patients At ASCO
  • Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial For EOquin(R) In Patients With Non Invasive Bladder Cancer
  • Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101
  • Oncothyreon Initiates Phase 1b Trial Of PX-12 In Patients With Advanced Metastatic Cancer
  • Proteolix Initiates Phase 2 Clinical Trial Of Carfilzomib In Patients With Relapsed Solid Tumors

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.